CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 66 enrolled
Drug / intervention
nitazoxanide +2 moredrug
Likely dose
nitazoxanide 500mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01770483
NCT01770483Phase 4Completed
CompareCT.gov

The Role Of Nitazoxanide, Interferon Alfa And Ribavirin In Treatment Of Hepatitis C Infected Type 2 Diabetic Patients

Services Institute of Medical Sciences, Pakistan·interventional·Posted Jan 17, 2013·Updated Sep 20, 2013

In Brief

A Phase 4 clinical trial evaluating nitazoxanide, conventional interferon alfa, and 1 other intervention for Hepatitis C, Chronic and DIABETES MELLITUS Type 2. Completed, enrolled 66 participants across 1 site.

Detailed Summary

The purpose of this study is to investigate if nitazoxanide used in combination with interferon alfa and ribavirin is effective in treating Hepatitis c infected type 2 Diabetic patients by improving their sustained viral response by more than 80%.Considering that the study is being conducted in a third world country like Pakistan, the standard treatment of hepatitis C is not cost effective. The aim is to introduce a new treatment comparable in efficacy to peginterferon and also cost effective.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C, Chronic, DIABETES MELLITUS Type 2
CountriesPakistan
CollaboratorsGetz Pharma

Timeline

Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJan 17, 2013
Enrollment StartJul 1, 2011
Primary CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 13.5 years ago

Interventions

nitazoxanidedrug

nitazoxanide 500mg twice daily

conventional interferon alfadrug

Inj interferon 3 Million International Units thrice weekly

Ribavirindrug

ribazole